(19)
(11) EP 3 538 106 A1

(12)

(43) Date of publication:
18.09.2019 Bulletin 2019/38

(21) Application number: 17869854.4

(22) Date of filing: 09.11.2017
(51) International Patent Classification (IPC): 
A61K 31/683(2006.01)
 A61K 31/506(2006.01)
(86) International application number:
PCT/US2017/060936
(87) International publication number:
WO 2018/089687 (17.05.2018 Gazette 2018/20)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 09.11.2016 US 201615347381

(71) Applicant: Signpath Pharma, Inc.
Sandy, UT 84092 (US)

(72) Inventor:
  • HELSON, Lawrence
    Quakertown, PA 18951 (US)

(74) Representative: Sonn & Partner Patentanwälte 
Riemergasse 14
1010 Wien
1010 Wien (AT)

   


(54) PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES